The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy

被引:105
作者
Buitrago, M
Lorenz, K
Maass, AH
Maass, SO
Keller, U
Schmitteckert, EM
Ivashchenko, Y
Lohse, MJ
Engelhardt, S
机构
[1] Univ Wurzburg, Rudolf Virchow Ctr, DFG, Res Ctr Expt Biomed, D-97078 Wurzburg, Germany
[2] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany
[3] Univ Wurzburg, Med Klin, D-97080 Wurzburg, Germany
[4] Sanofi Aventis, Div Cardiovasc, D-65926 Frankfurt, Germany
关键词
D O I
10.1038/nm1272
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypertrophy represents the major physiological response of the heart to adapt to chronically enhanced workload, but is also crucial in the development of heart failure. Although we know of numerous inducers of cardiac hypertrophy, little is known about mechanisms that limit cardiac hypertrophy. Here, we describe the transcriptional repressor NAB1 as an endogenous regulator of cardiac growth. We identified NAB1 as being upregulated in both mouse and human heart failure. Nab1 is highly expressed in mammalian cardiac myocytes and it inhibited cardiomyocyte hypertrophy through repression of its targets, transcription factor Egr. Transgenic mice with cardiac-specific overexpression of Nab1 showed that Nab1 is a potent inhibitor of cardiac growth in response to pathological stimuli in vivo. Nab1 overexpression suppressed adrenergically induced and pressure overload-induced hypertrophy, whereas physiological growth during development and in response to exercise was not affected. These findings implicate the Nab1-Egr1 axis as a crucial regulator of pathological cardiac growth.
引用
收藏
页码:837 / 844
页数:8
相关论文
共 35 条
  • [1] Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse
    Allen, DL
    Harrison, BC
    Maass, AH
    Bell, ML
    Byrnes, WC
    Leinwand, LA
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 2001, 90 (05) : 1900 - 1908
  • [2] The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo
    Bueno, OF
    De Windt, LJ
    Lim, HW
    Tymitz, KM
    Witt, SA
    Kimball, TR
    Molkentin, JD
    [J]. CIRCULATION RESEARCH, 2001, 88 (01) : 88 - 96
  • [3] Buvoli M, 2002, METHOD ENZYMOL, V346, P134
  • [4] Converging pathways and principles in heart development and disease: CV@CSH
    Chien, KR
    Olson, EN
    [J]. CELL, 2002, 110 (02) : 153 - 162
  • [5] Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways
    Crackower, MA
    Oudit, GY
    Kozieradzki, I
    Sarao, R
    Sun, H
    Sasaki, T
    Hirsch, E
    Suzuki, A
    Shioi, T
    Irie-Sasaki, J
    Sah, R
    Cheng, HYM
    Rybin, VO
    Lembo, G
    Fratta, L
    Oliveira-dos-Santos, AJ
    Benovic, JL
    Kahn, CR
    Izumo, S
    Steinberg, SF
    Wymann, MP
    Backx, PH
    Penninger, JM
    [J]. CELL, 2002, 110 (06) : 737 - 749
  • [6] Phenotyping hypertrophy - Eschew obfuscation
    Dorn, GW
    Robbins, J
    Sugden, PH
    [J]. CIRCULATION RESEARCH, 2003, 92 (11) : 1171 - 1175
  • [7] Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice
    Engelhardt, S
    Hein, L
    Wiesmann, F
    Lohse, MJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 7059 - 7064
  • [8] Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress
    Esposito, G
    Rapacciuolo, A
    Prasad, SVN
    Takaoka, H
    Thomas, SA
    Koch, WJ
    Rockman, HA
    [J]. CIRCULATION, 2002, 105 (01) : 85 - 92
  • [9] Hypertrophy of the heart - A new therapeutic target?
    Frey, N
    Katus, HA
    Olson, EN
    Hill, JA
    [J]. CIRCULATION, 2004, 109 (13) : 1580 - 1589
  • [10] EARLY GROWTH-RESPONSE PROTEIN 1(EGR-1) - PROTOTYPE OF A ZINC-FINGER FAMILY OF TRANSCRIPTION FACTORS
    GASHLER, A
    SUKHATME, VP
    [J]. PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 50, 1995, 50 : 191 - 224